reSee.it - Related Video Feed

The discussion centers on the collusion between the food and pharmaceutical industries, particularly how they manipulate public perception and policy to maintain unhealthy dietary habits. Calley Means highlights a Harvard study funded by the sugar industry that influenced the food pyramid, contributing to widespread health issues. He argues that food stamps disproportionately fund sugary drinks, exacerbating obesity and related diseases. Means recounts experiences with corporations like Coca-Cola, which have paid organizations to label health advocates as racist, thus silencing criticism of unhealthy products. He emphasizes the systemic nature of these issues, noting that healthcare institutions profit from keeping people sick rather than promoting health. The conversation critiques the reliance on pharmaceutical solutions, like Ozempic for obesity, which do not address the underlying dietary problems. Means calls for a shift in public policy to prioritize whole foods over processed options, advocating for a bottoms-up revolution in health awareness. He proposes that healthcare incentives should focus on prevention rather than treatment, suggesting that food should be viewed as medicine. The conversation concludes with a call for individuals to cultivate curiosity about their health and challenge the status quo, emphasizing the need for systemic change in how food and health are approached in America.

Calley Means shared his experience working as a consultant for Coca-Cola, revealing how the company employed tactics to undermine soda tax initiatives by labeling opponents as racist. He highlighted the alarming statistics around sugar consumption and its health impacts on children, including rising obesity and diabetes rates. Means described a three-part playbook used by Coke, which involved paying civil rights organizations to silence critics and influencing conservative think tanks to support soda subsidies. He expressed concern over the influence of processed food companies on nutrition research, noting that they spend significantly more on research than the NIH, often skewing findings to favor unhealthy products. Means emphasized that the healthcare system profits from treating chronic conditions rather than preventing them, with 93% of adults experiencing metabolic dysfunction. The conversation touched on the systemic issues within healthcare and food policy, where unhealthy food is subsidized while healthy options remain expensive. Means argued that the focus should shift to preventive measures, advocating for a public policy overhaul that prioritizes nutrition and health education. He also discussed the emergence of Ozempic, a weight-loss drug, and its promotion by media and healthcare professionals, many of whom are financially tied to pharmaceutical companies. Means criticized the lack of nutritional education in medical training and the reliance on medications rather than addressing root causes of health issues. Means and his sister, Dr. Casey Means, are working on a company called True Medicine, aimed at changing healthcare incentives to support preventive health measures. They plan to allow consumers to use tax-advantaged accounts for healthy food and wellness products, promoting a shift towards a healthier society. The discussion concluded with a focus on legacy and the importance of understanding the connection between diet, health, and overall well-being.

The discussion centers around the issue of obesity and the use of OIC (Obesity Intervention Drugs) in America, which the hosts argue is symptomatic of a larger problem in the healthcare system. Telly describes OIC as "liquefied anorexia," suggesting that it merely masks the root causes of obesity rather than addressing them. He criticizes the medical education system for neglecting nutrition training, citing an anecdote about a Stanford surgeon dismissing dietary interventions. Kelly highlights the alarming statistics of obesity in America, noting that 50% of teens are overweight or obese, compared to just 3% in Japan. He argues that the healthcare industry profits from managing chronic diseases rather than preventing them, with a focus on drugging patients instead of addressing lifestyle factors. The conversation touches on the influence of pharmaceutical companies on medical education and policy, revealing that many medical schools are funded by these companies, which affects the integrity of healthcare recommendations. The hosts discuss the economic implications of the obesity crisis, predicting that healthcare costs could consume 40% of GDP in the next 20 years. They emphasize the need for systemic change, advocating for a shift towards healthier food systems and incentivizing better lifestyle choices rather than relying on drugs like Ozempic. They also explore the historical context of the pharmaceutical industry, linking it to the rise of chronic conditions and the segmentation of medical specialties that prioritize profit over holistic health. The conversation concludes with a call to action for entrepreneurs and investors to focus on sustainable health solutions, emphasizing that the current trajectory is unsustainable and detrimental to American society. The hosts express a desire for a healthier future, advocating for a reevaluation of dietary practices and healthcare policies.

In this episode, Steven Bartlett speaks with Johann Hari, bestselling author, about the transformative effects and risks associated with the weight loss drug Ozempic. Johann shares his personal journey of losing three stone and the profound impact Ozempic had on his appetite, reducing his hunger by 80%. He discusses the cultural shift towards using drugs for weight loss after decades of promoting diet and exercise, noting that only 10% of people maintain significant weight loss through traditional methods. Johann highlights the extraordinary benefits of Ozempic, including its ability to reverse obesity and reduce health risks associated with being overweight. He mentions that the average user can lose 15% of their body weight in a year, with newer drugs potentially offering even greater results. However, he expresses concern over the 12 significant risks associated with these drugs, including muscle mass loss, potential suicidal feelings, and the grim reality that 70% of weight lost is often regained within a year of stopping the medication. The conversation touches on the societal implications of widespread drug use for weight loss, with Johann reflecting on his experiences at a party where he noticed many attendees had lost weight, attributing it to Ozempic. He recounts a moment of realization when a friend introduced him to the drug, leading him to explore its effects and the conflicting emotions surrounding its use. Johann emphasizes the need for a nuanced understanding of the drug's impact on mental health, particularly regarding eating disorders. He shares alarming statistics about the rise of eating disorders during the pandemic and warns that the accessibility of Ozempic could exacerbate these issues, especially among young people. The discussion also delves into the science behind Ozempic, explaining how it mimics the hormone GLP-1, which signals fullness. Johann notes that while the drug can help reduce cravings for unhealthy foods, it may also dampen the reward system in the brain, leading to concerns about its long-term psychological effects. As the conversation progresses, Johann reflects on the broader context of obesity and the food industry, arguing that the rise in obesity is linked to changes in food supply and societal pressures. He advocates for a comprehensive approach to addressing obesity, including regulatory measures similar to those used in Japan, where public health initiatives have successfully reduced obesity rates. Johann shares anecdotes from his research, including a compelling experiment with rats that demonstrated how exposure to unhealthy foods can alter their eating behavior. He discusses the importance of understanding the psychological factors that drive eating habits and the need for societal change to combat the obesity crisis. The episode concludes with Johann expressing hope that the conversation around Ozempic and weight loss drugs will lead to greater awareness of the underlying issues contributing to obesity. He emphasizes the importance of addressing the food environment and promoting healthier choices, while also acknowledging the complex relationship individuals have with food and body image.

The conversation revolves around health, fitness, and personal growth, with Chris Williamson and his guest discussing their past lifestyles and the evolution of their health consciousness. The guest reflects on a time when he lived a more reckless lifestyle, emphasizing that while there was a sense of freedom in being careless, it ultimately led to negative physical and mental health outcomes. He acknowledges that this realization is a continuous process rather than a one-time fix. They delve into the pressures of societal expectations regarding health and appearance, particularly among younger generations. A study reveals that a significant percentage of Gen Z is considering using GLP-1 drugs like Ozempic for weight loss, with women setting more ambitious targets than men. The guest warns that while these drugs may provide quick results, they can lead to muscle loss and are not a sustainable solution for long-term health. He advocates for a balanced approach to fitness that includes proper nutrition and exercise. The discussion touches on the importance of personal experience in learning life lessons, contrasting 2D lessons from advice with 3D lessons gained through firsthand experience. The guest shares insights from Bill Perkins' book *Die With Zero*, which encourages people to spend their wealth meaningfully rather than hoarding it. They explore the misconception that money equates to happiness, emphasizing that true fulfillment often comes from experiences rather than material wealth. The conversation also addresses the challenges of communication and assertiveness, particularly in relationships and professional settings. The guest reflects on how societal pressures and personal insecurities can hinder individuals from advocating for themselves. They discuss the paradox of feeling more comfortable standing up for friends than for oneself, highlighting the need for self-advocacy. As they transition to the topic of fitness and health, the guest shares his personal journey of weight loss and improved health through better nutrition and training. He recounts how he initially considered using GLP-1s but ultimately chose to focus on a healthier diet and exercise regimen, resulting in significant weight loss and improved well-being. The conversation shifts to societal attitudes towards body image and the hypocrisy of the fat acceptance movement in light of the popularity of weight loss drugs. The guest expresses frustration with the notion that body positivity should ignore health concerns, arguing that accountability is essential for personal growth. They discuss the changing landscape of nightlife and alcohol consumption among younger generations, noting a decline in drinking culture and a rise in alternative substances like cannabis. The guest highlights how this shift reflects broader societal changes and a growing awareness of health and wellness. The conversation concludes with reflections on the complexities of human behavior, particularly in the context of crime and morality. The guest expresses fascination with the motivations behind criminal behavior and the psychological factors that contribute to individuals' actions. They emphasize the importance of understanding these dynamics to foster empathy and insight into human nature.

Megyn Kelly hosts a wide‑ranging discussion with Piers Morgan, Eric Trump, and Calley Means that blends media critique, political strategy, and public‑health reform with personal anecdotes from the Trump orbit. The episode pivots around a centralized theme: the perceived rise of woke culture and its impact on broadcasting, journalism, and policymaking, including a highlight on Condé Nast and Teen Vogue as symbols of what the guests see as a woke establishment. Megyn frames the conversation with pride in a no‑nonsense, anti‑establishment stance and tees up a rundown of guests who embody different facets of the movement: Piers Morgan’s critique of woke culture and his new book, Woke Is Dead; Eric Trump’s reflections on presidential politics, media bias, and his family’s legal and political battles; and Calley Means’s health‑policy project, Maha, which advocates for systemic healthcare reform and healthier food policies. The dialogue weaves through contemporary hot topics—media double standards, the weaponization of government, and the push to “make America healthy again.” The interview with Calley Means spotlights a policy‑oriented critique of America’s health landscape: rampant obesity, the influence of ultra‑processed foods, and the role of government subsidies. Means describes a reform agenda that seeks to realign incentives toward wellness, reduce dependence on high‑priced drugs like Ozempic, and empower families with practical nutrition and access to better health outcomes. The guests also reflect on immigration, the labor market, and the need to prioritize American workers, with Megyn pressing for deportations of those here illegally unless lawful status is established, while also signaling a broader critique of the political class and the media ecosystem that amplifies partisan narratives. The episode closes with a candid exchange about 2028 political possibilities, the resilience of the MAGA movement, and Eric Trump’s personal assessment of leadership, media, and the path forward for a Republican administration. The conversation is anchored by personal anecdotes—from backstage dynamics to family stories, including exchanges about Barron Trump and the Trump Library—providing a candid portrait of a family and a political movement navigating today’s polarized climate.

The discussion centers on the use of Ozempic and other GLP-1 agonists for weight loss, highlighting both potential benefits and risks. Experts emphasize the importance of combining these medications with proper nutrition, resistance training, and lifestyle changes to avoid negative impacts on muscle mass and metabolism. Concerns are raised about the long-term health effects of relying solely on these drugs, particularly in children, and the need for a supportive food environment. The conversation critiques the pharmaceutical industry's influence on obesity treatment and stresses that while medications can assist, they should not replace foundational health practices. Ultimately, a holistic approach is deemed essential for sustainable weight management.

Johann Hari discusses his significant weight loss journey, which began after feeling self-conscious at a party where he noticed others had lost weight due to new weight loss drugs like Ozempic. These drugs, including Mounjaro and Triple G, can lead to substantial weight loss and reduce health risks associated with obesity, such as heart attacks and strokes. However, Hari expresses conflicted feelings about their use, recalling the history of diet drugs that often come with severe side effects. He undertook a year-long exploration of these drugs, interviewing supporters and critics, and found that they work differently from previous weight loss medications by mimicking the hormone GLP-1, which signals fullness. While many experience nausea initially, the drugs can lead to reduced food intake and altered cravings. Hari notes that nearly half of Americans express interest in these drugs, reflecting a cultural shift towards pharmaceutical solutions for weight management. He highlights the alarming rise in obesity rates linked to the consumption of processed foods, which undermine natural satiety signals. The drugs may help restore these signals but come with risks, including potential thyroid cancer and muscle mass loss. Hari warns against their misuse among those at healthy weights and emphasizes the need for careful consideration of the risks versus benefits. Ultimately, he concludes that while these drugs could be transformative, they also reflect deeper societal issues regarding food and health. He advocates for systemic changes to address obesity rather than relying solely on medication.

Tucker Carlson discusses skepticism towards new pharmaceutical products, particularly Ozempic, a diabetes drug that aids weight loss. Cali Means, founder of TruMed, argues that Ozempic is problematic for three main reasons. First, obesity is a symptom of deeper metabolic dysfunction, not a deficiency that can be solved with medication. He highlights the alarming rates of obesity and prediabetes in America, attributing these issues to corrupt food industry practices and government subsidies favoring processed foods. Second, he claims that Ozempic has severe side effects, including gastrointestinal issues and potential mental health risks, with many patients discontinuing use due to these problems. Third, Means points to systemic corruption within healthcare, where pharmaceutical companies influence medical guidelines and research funding, leading to a focus on lifelong drug dependency rather than addressing root causes of health issues. He emphasizes the need for a shift towards better nutrition and exercise, criticizing the current healthcare model that profits from chronic illness. Means concludes by advocating for a reevaluation of public health policies to prioritize metabolic health.

In this episode, Rich Roll speaks with Johann Hari about the weight loss drug Ozempic and its implications for health and society. Johann shares his personal experience with Ozempic, noting that he felt significantly less hungry after starting the medication, which he describes as a potential game changer in the fight against obesity. He emphasizes that obesity is linked to over 200 diseases and complications, making the risks of obesity a critical consideration when weighing the use of such drugs. Johann reflects on the societal pressures surrounding weight loss and the historical context of obesity, noting that the perception of obesity as a moral failing is deeply ingrained in culture. He discusses the mixed emotions he felt upon taking Ozempic, recognizing the benefits while grappling with feelings of guilt and the fear of being perceived as cheating. He argues that the conversation around these drugs should focus on the nuanced benefits and risks rather than falling into binary judgments of right or wrong. The discussion also touches on the broader implications of these drugs, comparing their potential impact to that of the smartphone revolution. Johann highlights the need for a balanced approach, acknowledging that while these drugs can help some individuals, they do not address the underlying environmental factors contributing to obesity. He shares insights from his research, including the importance of understanding the psychological drivers of eating and the potential for these drugs to disrupt established habits. Rich and Johann explore the risks associated with long-term use of weight loss drugs, including the possibility of regaining weight after discontinuation and the psychological effects that may arise. Johann expresses concern about the potential for these drugs to exacerbate eating disorders, particularly among young people who may seek them for aesthetic reasons rather than health. Throughout the conversation, Johann emphasizes the importance of personal responsibility and the need for individuals to engage with their health choices actively. He advocates for a holistic approach that combines the use of medications like Ozempic with lifestyle changes and education about nutrition. The episode concludes with a call for a deeper understanding of the complexities surrounding obesity and the societal structures that contribute to it, urging listeners to consider both the benefits and risks of new weight loss drugs while advocating for systemic change in the food environment.

The discussion highlights a significant decline in health across the U.S., with rising rates of chronic diseases, obesity, and mental health issues. The hosts, Dhru Purohit, Casey Means, and Calley Means, emphasize that the healthcare system is primarily focused on managing symptoms rather than addressing root causes, which they identify as metabolic dysfunction. They argue that the current model incentivizes sickness, as healthcare institutions profit from patients remaining unwell. Casey recounts her experience as a surgeon, realizing that traditional medical interventions often fail to address the underlying physiological issues causing disease. She shares a pivotal moment during a surgery where she recognized that despite performing procedures, she was not truly healing her patients. This realization led her to explore the importance of metabolic health and the need for a paradigm shift in how we approach health and wellness. Calley discusses the economic implications of chronic diseases, noting that they have become a lucrative business model for the healthcare industry. The conversation reveals that chronic conditions have become the primary focus of medical spending, with a staggering increase in their prevalence since the 1960s. They highlight that the system is designed to keep people dependent on medications rather than promoting preventive measures or lifestyle changes. The hosts stress the importance of understanding metabolic health, which they define as the body's ability to convert food into energy effectively. They argue that many chronic diseases stem from poor metabolic function, exacerbated by environmental factors, processed foods, and lifestyle choices. They advocate for a return to whole foods and natural diets, emphasizing that the confusion surrounding nutrition is a deliberate outcome of the food and pharmaceutical industries. They also discuss the role of modern technology in health management, such as continuous glucose monitors, which can provide real-time feedback on how food choices affect metabolic health. This empowers individuals to take control of their health by making informed decisions based on their body's responses. The conversation touches on the societal implications of the current health crisis, including the impact on children and the normalization of poor health. They call for a collective awakening to the realities of the healthcare system and encourage listeners to question conventional wisdom and take proactive steps toward better health. Ultimately, the hosts convey a message of hope, asserting that individuals can reclaim their health by understanding and addressing the root causes of chronic diseases. They advocate for a shift towards a more holistic approach to health that prioritizes metabolic function, community connection, and personal empowerment.

In the discussion, Calley Means, a prominent food industry whistleblower, shares insights from her book *Good Energy*, co-authored with Casey Means. The book emphasizes the interconnectedness of chronic diseases and critiques the medical system's siloed approach to healthcare, which often overlooks the root causes of conditions like diabetes and obesity. Casey's realization during her medical training highlighted how patients with chronic conditions often had multiple comorbidities, yet the focus remained on treating symptoms rather than understanding underlying issues. Means argues that the healthcare system profits from chronic diseases, with pharmaceutical companies heavily influencing medical education and practices. She reveals that 50% of Stanford Medical School's funding is linked to pharmaceutical interests, which shapes the standard of care towards drug prescriptions rather than lifestyle changes. The book advocates for a paradigm shift in how chronic diseases are perceived and treated, promoting a focus on metabolic health through diet, exercise, and holistic approaches. Means also discusses the alarming rise in childhood obesity and related health issues, attributing it to systemic failures in food policy and healthcare. She highlights the need for informed consent in medical treatment and the importance of empowering patients to question prescribed medications. The conversation touches on the influence of food companies in shaping dietary guidelines and public perception, emphasizing the need for transparency and accountability in nutrition research. Ultimately, *Good Energy* serves as a guide for individuals seeking to navigate the broken healthcare system and adopt healthier lifestyles, advocating for both bottom-up and top-down changes to improve public health.